Dual Effect of Chemo-PDT with Tumor Targeting Nanoparticles Containing iRGD Peptide

Pharmaceutics. 2023 Feb 11;15(2):614. doi: 10.3390/pharmaceutics15020614.

Abstract

Nanotechnology, including self-aggregated nanoparticles, has shown high effectiveness in the treatment of solid tumors. To overcome the limitations of conventional cancer therapies and promote therapeutic efficacy, a combination of PDT and chemotherapy can be considered an effective strategy for cancer treatment. This study presents the development of tumor-targeting polysialic acid (PSA) nanoparticles for chemo-PDT to increase the cellular uptake and cytotoxic effect in cancer cells. Chlorin e6 (Ce6), a photosensitizer, and the iRGD peptide (sequence; cCRGDKGPDC) were conjugated to the amine of N-deacetylated PSA. They generate reactive oxygen species (ROS), especially singlet oxygen (1O2), and target integrin αvβ3 on the cancer cell surface. To offer a chemotherapeutic effect, doxorubicin (Dox) was assembled into the core of hydrophobically modified PSA by connecting it with Ce6; this was followed by its sustained release from the nanoparticles. These nanoparticles are able to generate ROS under 633 nm visible-light irradiation, resulting in the strong cytotoxicity of Dox with anticancer effects in HCT116 cells. PSA nanoparticles with the dual effect of chemo-PDT improve conventional PDT, which has a poor ability to deliver photosensitizers to cancer cells. Using their combination with Dox chemotherapy, rapid removal of cancer cells can be expected.

Keywords: combination therapy; iRGD; nanoparticle; photodynamic therapy; tumor targeting peptide.

Grants and funding

This research was supported by a grant (21153MFDS601) from Ministry of Food and Drug Safety in 2022 and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MIST) (2022R1F1A1076216).